Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

CNM-Au8 Lessens Vision Problems in RRMS Patients in Phase 2 Trial

August 17, 2022

Clene to Move Forward in MS Despite COVID-19-Halted Phase II Trial

August 16, 2022

CNM-Au8 Displays Positive Topline Results in Multiple Sclerosis, Supportive of Phase 3 Trial

August 16, 2022

CNM-Au8 Reduces Mortality in ALS, Prenatal Exposure to ASMs Increases Neurodevelopmental Disorders, FDA Grants Tentative Approval to FT218

July 23, 2022

EU Committee Urges Orphan Drug Status for Clene’s CNM-Au8 for ALS

July 22, 2022

CNM-Au8 Shows Continued Decreases in ALS Mortality, Updated Open-Label Findings Show

July 21, 2022

Early CNM-Au8 Treatment Leads to Significant Survival Benefit in Study

July 18, 2022

Decreased Mortality in Amyotrophic Lateral Sclerosis Seen in Open-Label Extension Study of Nanocrystalline Gold

July 18, 2022

Burr bill, Novartis makeover, ALS update: a BioCentury podcast

July 18, 2022

Clene’s CNM-Au8 boosts survival in amyotrophic lateral sclerosis trial

July 15, 2022

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved